Literature DB >> 2787060

Thrombosis of portal vein in absence of hepatic disease.

L Belli1, F Romani, F Riolo, G Rondinara, P Aseni, M Di Stefano, L Contorni, M Bini.   

Abstract

Of 602 patients referred for portal hypertension during a 20 year period, 18 children (mean age of 5.0 years) and 29 adults (mean age of 26.5 years) had thrombosis in the portal bed with a healthy liver (7.8 per cent incidence). In 29 of the 47 patients we studied, the causative factor remained obscure. Variceal hemorrhage occurred in all and was the indication for our observation and treatment. In 11 adult patients (mean age of 22.1 years), surgical treatment was not performed because of reluctance of the patient or because of technical reasons: nine of the patients rebled and one patient died because of massive bleeding. Direct procedures on esophageal varices had a high rate of rebleeding (seven of 11 patients) independent of the age of the patient when the operation was performed. In 13 patients, shunting offered a good chance of long term protection: three of the 13 rebled at a mean follow-up study of 5.7 years. No recurrence of bleeding was observed in 15 patients when variceal eradication had been obtained after chronic endoscopic sclerotherapy at one to eight years of follow-up study (mean of 3.9 years). The data from this study indicate that sclerotherapy should be the first choice of treatment to control recurrent bleeding in extrahepatic portal hypertension caused by thrombotic obstruction, particularly in the young patient.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787060

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  8 in total

1.  Transabdominal modified devascularization procedure with or without esophageal stapler transection--an operation adequate for effective control of a variceal bleed. Is esophageal stapler transection necessary?

Authors:  M Johnson; S Rajendran; T G Balachandar; D Kannan; S Jeswanth; P Ravichandran; R Surendran
Journal:  World J Surg       Date:  2006-08       Impact factor: 3.352

Review 2.  Transhepatic fibrinolysis of mesenteric and portal vein thrombosis in a patient with ulcerative colitis: a case report.

Authors:  Alfredo Guglielmi; Francesca Fior; Orsolya Halmos; Gian Franco Veraldi; Lorenzo Rossaro; Andrea Ruzzenente; Claudio Cordiano
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

3.  Occult myeloproliferative neoplasms: not so occult any more.

Authors:  Dhauna Karam; Veena Iyer; Bharat Agrawal
Journal:  BMJ Case Rep       Date:  2017-05-30

4.  Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies.

Authors:  Mats Ogren; David Bergqvist; Martin Björck; Stefan Acosta; Henry Eriksson; Nils H Sternby
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

5.  Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients.

Authors:  Mahmoud A Amin; Mohamed M el-Gendy; Ibrahim E Dawoud; Ashraf Shoma; Ahmed M Negm; Talal A Amer
Journal:  World J Surg       Date:  2009-08       Impact factor: 3.352

6.  Surgical management of extrahepatic portal hypertension and variceal bleeding.

Authors:  H Orozco; T Takahashi; M A Mercado; E Prado; C Chan
Journal:  World J Surg       Date:  1994 Mar-Apr       Impact factor: 3.352

7.  Long term outcome after surgery for extrahepatic portal vein thrombosis.

Authors:  P D Losty; M J Lynch; E J Guiney
Journal:  Arch Dis Child       Date:  1994-11       Impact factor: 3.791

8.  The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.

Authors:  Ipek Yonal; Binnur Pinarbası; Fehmi Hindilerden; Veysel Sabri Hancer; Meliha Nalcaci; Sabahattin Kaymakoglu; Reyhan Diz-Kucukkaya
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.